Diagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting
- 1 September 2025
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (Suppl 3) , 19-22
Abstract
Rheumatologists and other nondermatologists often encounter patients with psoriatic arthritis (PsA) who present with cutaneous diseases that mimic psoriasis (PsO). Cutaneous disorders including tinea, seborrheic dermatitis, eczema, pityriasis rubra pilaris, syphilis, or cutaneous lymphoma are commonly mistaken for PsO. It is crucial for rheumatologists and other nondermatologists to recognize alternative conditions and to consider referral to dermatology when skin disease is not responding to therapy. Correct diagnosis is important when assessing disease severity in clinical practice as well. Although the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) are gold standards for physician- and patient-reported outcomes in clinical trials, they are not practical to deploy in busy clinical practice. Use of a physician global assessment (PGA), body surface area using a handprint method, and informal patient-reported outcomes can be useful in documenting the burden of disease. A treat-to-target approach using a PGA of clear/almost clear is ideal. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting, a 2-part workshop was conducted for rheumatologists to first review skin disorders commonly mistaken for PsO, and second, to review outcome measures best suited for clinical practice.Keywords
This publication has 9 references indexed in Scilit:
- Disease Assessment in PsoriasisIndian Journal of Dermatology, 2023
- Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disordersJournal of the American Academy of Dermatology, 2023
- PsoriasisThe Lancet, 2021
- Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and TricksJournal of Clinical Medicine, 2020
- Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR )British Journal of Dermatology, 2019
- Using the Physician Global Assessment in a Clinical Setting to Measure and Track Patient OutcomesJAMA Dermatology, 2015
- Patient-reported outcome measures in psoriasis: the good, the bad and the missing!British Journal of Dermatology, 2015
- Product of the Physician Global Assessment and body surface area: A simple static measure of psoriasis severity in a longitudinal cohortJournal of the American Academy of Dermatology, 2013
- Measures used in specifying psoriasis lesion(s), global disease and quality of life: A systematic reviewJournal of Dermatological Treatment, 2007